国际生殖健康/计划生育杂志
國際生殖健康/計劃生育雜誌
국제생식건강/계화생육잡지
JOURNLA OF INTERNATIONAL REPRODUCTIVE HEALTH/FAMILY PLANNING
2015年
5期
429-432
,共4页
欧阳冬香%伍琼芳
歐暘鼕香%伍瓊芳
구양동향%오경방
促性腺素释放激素%黄体保持%生殖技术,辅助%受精,体外%胚胎移植%促性腺激素释放激素激动剂
促性腺素釋放激素%黃體保持%生殖技術,輔助%受精,體外%胚胎移植%促性腺激素釋放激素激動劑
촉성선소석방격소%황체보지%생식기술,보조%수정,체외%배태이식%촉성선격소석방격소격동제
Gonadotropin-releasing hormone%Corpus luteum maintenance%Reproductive techniques,assisted%Fertilization in vitro%Embryo transfer%Gonadotropin-releasing hormone agonist
在辅助生殖技术(assisted reproduction technique,ART)周期中,控制性超促排卵及取卵后容易导致黄体功能不全,为了解决这个问题,常规需要在ART周期中进行黄体支持(luteal phase support,LPS)。目前疗效肯定的LPS方案是单独或者联合使用不同剂量孕激素和人绒毛膜促性腺激素(human chorionic gonadotropin,hCG),但hCG会增加卵巢过度刺激综合征(ovarian hyperstimulation syndrome,OHSS)发生的风险。近年来有学者发现在LPS中添加促性腺激素释放激素激动剂(gonadotropin-releasing hormone agonist, GnRHa)不仅可减少OHSS的发生,还能获得良好的妊娠结局。虽然如此,目前有关GnRHa使用剂型、剂量、给药途径、时间、机制和效果仍不清楚,尚需进一步探索。
在輔助生殖技術(assisted reproduction technique,ART)週期中,控製性超促排卵及取卵後容易導緻黃體功能不全,為瞭解決這箇問題,常規需要在ART週期中進行黃體支持(luteal phase support,LPS)。目前療效肯定的LPS方案是單獨或者聯閤使用不同劑量孕激素和人絨毛膜促性腺激素(human chorionic gonadotropin,hCG),但hCG會增加卵巢過度刺激綜閤徵(ovarian hyperstimulation syndrome,OHSS)髮生的風險。近年來有學者髮現在LPS中添加促性腺激素釋放激素激動劑(gonadotropin-releasing hormone agonist, GnRHa)不僅可減少OHSS的髮生,還能穫得良好的妊娠結跼。雖然如此,目前有關GnRHa使用劑型、劑量、給藥途徑、時間、機製和效果仍不清楚,尚需進一步探索。
재보조생식기술(assisted reproduction technique,ART)주기중,공제성초촉배란급취란후용역도치황체공능불전,위료해결저개문제,상규수요재ART주기중진행황체지지(luteal phase support,LPS)。목전료효긍정적LPS방안시단독혹자연합사용불동제량잉격소화인융모막촉성선격소(human chorionic gonadotropin,hCG),단hCG회증가란소과도자격종합정(ovarian hyperstimulation syndrome,OHSS)발생적풍험。근년래유학자발현재LPS중첨가촉성선격소석방격소격동제(gonadotropin-releasing hormone agonist, GnRHa)불부가감소OHSS적발생,환능획득량호적임신결국。수연여차,목전유관GnRHa사용제형、제량、급약도경、시간、궤제화효과잉불청초,상수진일보탐색。
The luteal phase defect frequently occurs after the controlled ovarian stimulation and follicular aspiration in assisted reproduction techniques (ARTs). As a clinical routine, luteal phase support (LPS) is recommended in ART cycles. The LPS treatment with definite curative effect is progesterone alone or progesterone plus hCG. However, hCG is associated with the increased risk of OHSS. Recently, it was showed that the added GnRH agonist in LPS treatment could decrease the OHSS risk, but also improve the outcomes of pregnancy. It is necessary to explore further the formulation of GnRH agonist, the minimal effective dose and the most effective timing and protocol, as well as its exact mechanism.